Coagulant Therapeutics Corporation

Coagulant Therapeutics leverages nearly 100 years of industry experience in both Hematology and Biologics research to develop a novel pipeline of therapies targeted at acute bleeding and its adjacencies. These are areas of high unmet need and where little or no pharmaceutical therapies exist today. Our lead molecule, CT-001, is an 2nd generation FVIIa engineered for enhanced potency and rapid clearance. The initial indication is in women's health for the treatment of severe postpartum hemorrhage, where we have been granted orphan drug designation. CT-003 is an antibody approach targeting activated protein C for the treatment of trauma designed to not only treat bleeding but also to prevent organ failure. Importantly, this creates and opportunity for a pipeline of molecules that should have additive or synergistic affects and limit the potential to cannabolize the lead.